CELL INTELLIGENCE · 肿瘤细胞治疗研究

体弱患者接受 ciltacabtagene autoleucel 治疗的真实世界疗效和安全性：国际血液和骨髓移植研究中心的分析

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant

Cilta-cel 在体弱 RRMM 中仍然有效，但衰弱与生存期缩短和毒性增加相关，支持制定个体化的 CAR-T 策略。

BCMA 靶向治疗失败后复发/难治性多发性骨髓瘤中 teclistamab 的挽救治疗结局：系统评价与 meta 分析

Salvage outcomes with teclistamab after BCMA-directed therapy failure in relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

Teclistamab 在 BCMA 治疗失败后显示出有意义的活性，可能代表一种挽救选择。然而，鉴于证据确定性为低至极低，疗效估计必须谨慎解读。需要前瞻性生物标志物分层试验，以优化 BCMA 靶向序列并识别最可能获益的患者。

免疫治疗时代将姑息治疗整合至复发/难治性多发性骨髓瘤：叙述性综述

Integrating Palliative Care into Relapsed/Refractory Multiple Myeloma in the Immunotherapy Era: A Narrative Review.

多发性骨髓瘤的单细胞图谱定义了恶性原型和增殖状态

A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.

辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案

Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy.

多发性骨髓瘤中的降阶梯治疗试验：过去、现在和未来

De-escalation trials in multiple myeloma: past, present and future.

CAR-T 细胞治疗受者的急性肾损伤：临床特征及对死亡率的影响

Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell therapy: Clinical Characteristics and Impact on Mortality.

超越传统嵌合抗原受体：拓展 CAR-T 细胞疗法中的可靶向抗原版图

Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy.

智胜抗原逃逸：用于血液系统恶性肿瘤持久缓解的下一代 CAR-T 细胞工程策略

Outsmarting Antigen Escape: Next-Generation CAR T Cell Engineering Strategies for Durable Remissions in Hematologic Malignancies.

中低收入国家学术型与床旁 CAR-T 细胞治疗的当前格局

Current landscape of academic and point of care CAR-T cell therapy in low-middle income countries.